Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Sep;99(9):e159-61.
doi: 10.3324/haematol.2014.106740. Epub 2014 Jun 27.

Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients

Marco Montillo  1 , Alessandra Tedeschi  2 , Gianluca Gaidano  3 , Marta Coscia  4 , Valeria Belsito Petrizzi  5 , Ester Orlandi  6 , Nicola Cascavilla  7 , Paolo Ghia  8 , Marina Motta  9 , Andrea Gallamini  10 , Anna Maria Frustaci  2 , Davide Rossi  3 , Lorenzo De Paoli  3 , Michele Nichelatti  11 , Enrica Morra  2 , Massimo Massaia  4
Affiliations

Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients

Marco Montillo et al. Haematologica. 2014 Sep.
No abstract available

Keywords: bendamustine; effective treatment; relapsed/refractory chronic lymphocytic leukemia.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Progression-free survival (PFS) after BenCam (A); Re-treatment-free survival according to response (B).
See this image and copyright information in PMC

References

    1. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99(10):3554–61. - PubMed
    1. Montillo M, Tedeschi A, Petrizzi VB, Ricci F, Crugnola M, Spriano M, et al. An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia. Blood. 2011;118(15):4079–85. - PubMed
    1. Elter T, James R, Busch R, Winkler D, Ritgen M, Böttcher S, et al. Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia. Leukemia. 2012;26(12):2549–52. - PubMed
    1. Lepretre S, Aurran T, Mahé B, Cazin B, Tournilhac O, Maisonneuve H, et al. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood. 2012;119(22):5104–10. - PubMed
    1. Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27(26):4378–84. - PubMed

MeSH terms

LinkOut - more resources